Development of a therapeutic nanobody targeting brain tnfa for the treatment of alzheimer disease

Active Project Grant Awarded Last action

Award ID
R42AG080864
Recipient
Awarding agency
Obligated
$2,499,561

Award facts

Assistance listing
93.866 Aging Research
Completion date 86% complete
Place of performance
Union, NJ 07083, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
This project seeks to advance the development of humanized tnfα inhibitors (inns) as a novel therapeutic approach for alzheimer's disease (ad). Our innovative inns are designed to effectively inhibit tnfα while crossing the blood-brain barrier, targeting the neuroinflammatory processes central to ad pathology. Building on phase i achievements, which included identifying inns with high tnfα inhibitory activity and favorable blood-brain barrier permeability, phase II will focus on rigorous preclinical evaluations in human-induced neurons, APP- humanized rats, and familial and late-onset ad RAT models. We will optimize INN formulations, characterize pharmacologic and toxicologic parameters, assess their immunogenicity, and begin establishing manufacturing processes for IND filing and clinical development. The success of this project could lead to a transformative treatment for ad, addressing a critical unmet need in neurodegenerative disease management.

Transactions

Action Obligated Date
Amendment $1,519,969
Original award $979,592

Quick answers

Who received award R42AG080864?

R42AG080864 was awarded to Nanonewron LLC by National Institute on Aging (National Institutes of Health) on July 1, 2023.

How much is award R42AG080864 worth?

$2,499,561 has been obligated on R42AG080864.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login